Linezolid was the first clinically applied agent from the oxazolidinone class, and AZD2563, a new agent, is described here. Five hundred and twenty-five streptococcal isolates were tested, including β-haemolytic (266) and viridans group (259) 
Introduction
Resistance to antimicrobials among Streptococcus species has been reported with great regularity over the last 10-15 years. [1] [2] [3] [4] Use of macrolides has been associated with susceptibility changes among streptococcal species including β-haemolytic strains. 4 Like the pneumococci, viridans group streptococcal species have acquired high rates of resistance to penicillin and other β-lactams, often attributed to altered penicillin binding protein targets. 2 These threats to contemporary streptococcal infection chemotherapy have fostered the development of new classes of antimicrobial agents (everninomicins, oxazolidinones, streptogramins, lipopeptides, etc.) that have been focused toward these Gram-positive pathogens. 5, 6 This study examined the in vitro characteristics of AZD2563, 7, 8 a new once-daily oxazolidinone, tested by reference susceptibility test methods against Streptococcus species other than Streptococcus pneumoniae. 9
Materials and methods

Antimicrobial agents
The comparator drugs tested were obtained from the United States manufacturers and AZD2563 was provided by AstraZeneca (Macclesfield, UK). The antimicrobials included: linezolid, 6 quinupristin-dalfopristin, vancomycin, erythromycin, clindamycin, gentamicin, levofloxacin and penicillin.
Bacterial isolates
The 525 strains tested were from various North American surveillance collections processed in the last 12 months by the JMI Laboratories (North Liberty, IA, USA). These strains included: viridans group streptococci (259 strains) and β-haemolytic streptococci (five serogroups, 266 strains). Each strain was identified by two or more laboratories and represented isolates derived from recent clinical cases. For 126 viridans group streptococci, high confidence identification (≥85%) to species level could not be made; these strains were classified as viridans group, NOS (not otherwise speciated). The remaining strains were identified as follows: Streptococcus anginosis (four strains), Tel: +1-319-665-3370; Fax: +1-319-665-3371; E-mail: ronald-jones@jmilabs.com strain), and β-haemolytic streptococci from groups A (112 strains), B (132 strains), C (11 strains), F (one strain) and G (10 strains). All viridans group strains were isolated from bloodstream infections, and the β-haemolytic isolates came from cultures of blood, wounds and the upper airway.
Susceptibility testing
All strains were tested by the NCCLS broth microdilution method. 9 Broth microdilution trays were prepared in frozen form by Trek Diagnostics (Westlake, OH, USA) and stored at -80°C until used. Antimicrobials were diluted in MuellerHinton broth with 5% lysed horse blood and the final inoculum was 5 × 10 5 cfu/mL, confirmed by regular colony counts. Quality control (QC) strains included fastidious (S. pneumoniae ATCC 49619) and rapidly growing species (Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212). All QC results were within control ranges published by the NCCLS 10 or product manufacturer (AstraZeneca). The rate of resistance among these strains to the antimicrobials cited ranged from nil to only 0.8%. The rates of resistance to the other antimicrobial agents tested (erythromycin, clindamycin, gentamicin, penicillin) were significantly higher, 9.6-50.0%, thus characterizing the challenge collection. Table 1 also shows the antimicrobial activity of the nine antimicrobial agents tested against the 266 β-haemolytic streptococci. The oxazolidinones, AZD2563 and linezolid, again showed equal potency (MIC 90 2 mg/L). Among the β-haemolytic streptococci, only 1.5% of isolates were penicillin resistant, but 16.9% were resistant to erythromycin. Clindamycin and levofloxacin were active against ≥93.6%.
Results
When analysing all 525 streptococcal isolates tested, AZD2563 and linezolid had nearly identical MIC ranges (0.06-2 mg/L of AZD2563 compared with 0.12-2 mg/L of linezolid) as well as MIC 50 and MIC 90 results. However, Figure 1 demonstrates that AZD2563 had a slight potency Table 1 . In vitro activity of AZD2563 compared with that of eight other antimicrobial agents tested against 259 strains of viridans group streptococci and 266 strains of β-haemolytic streptococci a Susceptibility as determined by NCCLS criteria. 10 An indication of susceptibility at <2 mg/L (that used for linezolid) could be applied to AZD2563 (100.0% susceptible) for comparison purposes only. 
Discussion
Linezolid has established the clinical utility of the oxazolidinone class for the therapy of problematic Gram-positive infections. 6 The spectrum of the oxazolidinones remains nearly complete, with only very rare occurrences of resistant S. aureus or enterococci being seen following long-term treatment with linezolid. 6 AZD2563 compared favourably with linezolid when tested against streptococci (viridans group and β-haemolytic species) 7, 8 and the early results from pharmacodynamic studies indicate the potential for once-daily dosing schedules. 11 We eagerly await the results of in vivo clinical trials and expanded pharmacokinetic data.
